Jago 2007.

Methods	Randomised controlled trial. Randomisation was performed using a computer‐generated table of random numbers, which were labelled on envelopes containing the drug (ergometrine or oxytocin).
Participants	510 consenting normotensive women with singleton pregnancies and no proteinuria at a hospital in Nigeria. Excluded those with history of hypertensive disorders of pregnancy, hypertension, chronic renal disease, endocrine disorders, vascular or cardiac disease, on anticoagulant therapy, having epidural anaesthesia, with allergy to 1 of the drugs under study, and those with intended instrumental/operative delivery.
Interventions	At delivery of the anterior shoulder: A. oxytocin 10 IU IV (n = 256). B. ergometrine 0.5 mg IM (n = 254). Management of the third stage of labour not otherwise described. Technique for measurement of blood loss not described.
Outcomes	Elevated blood pressure (> 140/90 mmHg). Estimated blood loss (mL).
Notes	Dates of study: January 2001 – December 2002 Funding sources: not reported Declarations of interest: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated table of random numbers.
Allocation concealment (selection bias)	Unclear risk	Quote: “The numbers were clearly labelled on envelopes containing a particular oxytocic”, however it is unclear whether the envelopes were sealed and opaque.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Blinding is not described, but it is unlikely that personnel were blinded as different quantities of each drug were administered.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Report does not include enough information to assess whether there was attrition.
Selective reporting (reporting bias)	Unclear risk	Protocol unseen.
Other bias	Unclear risk	No data.